BRL Medicine 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
35 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bimzelx (bimekizumab-bkzx) / UCB
BeNeBio, NCT04340076: Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Active, not recruiting
4
244
Europe
Secukinumab, Cosentyx, Ixekizumab, Taltz, Brodalumab, Kyntheum, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tildrakizumab, Ilumetri, Bimekizumab, Bimzelx
Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Belgium Health Care Knowledge Centre, University Hospital, Ghent
Psoriasis, Psoriasis Vulgaris
12/25
12/25
NCT05499416: Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

Withdrawn
4
20
NA
Bimekizumab, BIMZELX®
Innovaderm Research Inc., Ciusss de L'Est de l'Île de Montréal
Psoriasis Vulgaris, Active Psoriatic Arthritis
09/23
04/24
NCT06336343: Bimekizumab in Plaque Psoriasis

Recruiting
4
60
US
Bimekizumab
Icahn School of Medicine at Mount Sinai, UCB Pharma, Psoriasis Treatment Center of Central New Jersey
Plaque Psoriasis
10/25
10/25
BE RADIANT, NCT03536884 / 2017-003784-35: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Checkmark Efficacy and safety data from BE RADIANT in moderate to severe plaque psoriasis
Apr 2021 - Apr 2021: Efficacy and safety data from BE RADIANT in moderate to severe plaque psoriasis
Checkmark From BE RADIANT trial for psoriasis at AAD 2021
Feb 2021 - Feb 2021: From BE RADIANT trial for psoriasis at AAD 2021
Checkmark From BE RADIANT trial for psoriasis
More
Completed
3
743
Europe, Canada, US, RoW
Bimekizumab, UCB4940, Secukinumab, COSENTYX®, Placebo, PBO
UCB Biopharma SRL
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
09/19
08/23
BE HEARD I, NCT04242446 / 2019-002550-23: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Hourglass Jan 2023 - Jun 2023 : Data from BE HEARD I trial for moderate-to-severe hidradenitis suppurativa
Completed
3
505
Europe, Canada, US, RoW
Bimekizumab, UCB4940, Placebo, PBO
UCB Biopharma SRL
Hidradenitis Suppurativa
04/22
02/23
BE MOBILE 1, NCT03928704 / 2017-003064-13: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

Checkmark Data from BE MOBILE 1 and BE MOBILE 2 trials for active axial spondyloarthritis (axSpA)
Jan 2023 - Jan 2023: Data from BE MOBILE 1 and BE MOBILE 2 trials for active axial spondyloarthritis (axSpA)
Checkmark From BE MOBILE 1 trial for axial spondyloarthritis
Jan 2022 - Jan 2022: From BE MOBILE 1 trial for axial spondyloarthritis
Completed
3
274
Europe, Japan, US, RoW
Bimekizumab, BKZ, UCB4940, Placebo, PBO
UCB Biopharma SRL
Nonradiographic Axial Spondyloarthritis
06/22
04/23
BE BRIGHT, NCT03598790 / 2016-003427-30: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Checkmark Efficacy and safety data from BE SURE and BE BRIGHT trials for moderate to severe plaque psoriasis
Sep 2021 - Sep 2021: Efficacy and safety data from BE SURE and BE BRIGHT trials for moderate to severe plaque psoriasis
Checkmark Efficacy and safety data from BE BRIGHT open-label extension trial for psoriasis
Aug 2021 - Aug 2021: Efficacy and safety data from BE BRIGHT open-label extension trial for psoriasis
Completed
3
1353
Europe, Canada, Japan, US, RoW
Bimekizumab, UCB4940
UCB Biopharma SRL
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
11/23
11/23
BE TOGETHER, NCT06425549: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Recruiting
3
168
Europe, Canada, Japan, US, RoW
bimekizumab, BKZ, UCB4940, ustekinumab, USTE, placebo
UCB Biopharma SRL
Moderate to Severe Plaque Psoriasis
08/28
11/30
BE UNIQUE, NCT06506916: A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Recruiting
3
90
Europe, US
bimekizumab, BKZ
UCB Biopharma SRL
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
04/26
03/28
NCT06624228: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

Recruiting
3
550
Europe, Canada, Japan, US, RoW
Bimekizumab, Risankizumab, Placebo
UCB Biopharma SRL
Psoriatic Arthritis
03/26
07/26
NCT06668181: An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Recruiting
3
40
Europe, Canada
Bimekizumab
UCB Biopharma SRL
Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
02/28
06/30
NCT06921850: A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

Recruiting
3
40
US
Bimekizumab
UCB Biopharma SRL
Hidradenitis Suppurativa
03/27
05/29
BE SHINING, NCT06011733: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

Completed
3
133
RoW
Placebo, Bimekizumab, BKZ
UCB Biopharma SRL
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
02/25
02/25
BE VITAL, NCT04009499 / 2018-004725-86: A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Active, not recruiting
3
1131
Europe, Canada, Japan, US, RoW
Bimekizumab, BKZ, UCB4940
UCB Biopharma SRL
Psoriatic Arthritis
05/26
05/26
BE HEARD EXT, NCT04901195 / 2020-004179-42: A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Active, not recruiting
3
658
Europe, Canada, Japan, US, RoW
Bimekizumab, UCB4940
UCB Biopharma SRL
Hidradenitis Suppurativa
07/26
07/26
BE MOVING, NCT04436640 / 2019-004163-47: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Active, not recruiting
3
508
Europe, Japan, US, RoW
Bimekizumab, BKZ, UCB4940
UCB Biopharma SRL
Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
08/26
08/26
BE CONNECTED, NCT04718896 / 2020-001724-34: A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

Completed
2
41
Europe, Canada, US
bimekizumab, BKZ, UCB4940
UCB Biopharma SRL
Moderate to Severe Plaque Psoriasis
03/25
03/25
EARLYPSO, NCT06742333: Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?

Recruiting
2
40
Europe
Bimekizumab, Clobetasol
Centre Hospitalier Universitaire de Nice
Psoriasis
04/28
10/28
NCT05292131: A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Completed
1
121
Europe, US
bimekizumab, BKZ; UCB4940
UCB Biopharma SRL
Healthy Study Participants
01/23
01/23
BE CARING, NCT06888193: A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Recruiting
1
20
Canada
Bimekizumab, Bimzelx®
UCB Biopharma SRL
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
05/27
05/27
NCT06786936: Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms

Recruiting
N/A
50
Europe
Secukinumab, N/A (Not applicable), Bimekizumab, Ixekizumab, Placebo
NHS Greater Glasgow and Clyde, University of Glasgow, Medical Research Council
Psoriatic Arthritis, Depression, Psoriatic Plaque
02/27
04/27
BRL-301 / BRL Medicine
NCT05381181: Safety and Efficacy Evaluation of Next-generation CD19-UCART

Not yet recruiting
1
20
NA
CD19-UCART
Bioray Laboratories, The First Affiliated Hospital of Zhengzhou University
Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
05/24
05/26
NCT05859997: Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases

Enrolling by invitation
N/A
15
RoW
BRL-301, Allogeneic Anti-CD19 CAR T cells
Bioray Laboratories, Shanghai Changzheng Hospital
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated Systemic Vasculitis, Antiphospholipid Syndrome
05/24
05/25
NCT05988216: Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

Recruiting
N/A
12
RoW
BRL-301, Allogeneic Anti-CD19 CAR T cells
Bioray Laboratories, First Affiliated Hospital of Zhejiang University
Systemic Lupus Erythematosus (SLE)
12/24
09/25
BRL-201 / BRL Medicine
2022-BRL-201, NCT05741359: The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Recruiting
1
18
RoW
CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection, BRL-201
Bioray Laboratories, Institute of Hematology ＆ Blood Diseases Hospital，Chinese Academy of Medical Sciences, Zhejiang University, Wuhan Union Hospital, China
Non-hodgkin Lymphoma,B Cell
01/24
03/24
2019-CAR-00CH1, NCT04213469: PD1-CD19-CART in Patients With r/r B-cell Lymphoma

Completed
N/A
20
RoW
PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells, PD1-CD19-CART
Bioray Laboratories, First Affiliated Hospital of Zhejiang University
B-cell Lymphoma
11/21
11/23
BRL-101 / BRL Medicine
NCT05577312: Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

Enrolling by invitation
1
9
RoW
BRL-101, BRL-101 autologous hematopoietic stem and progenitor cells injection
Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University
Beta-Thalassemia
08/25
09/26
NCT06287099: Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease

Not yet recruiting
N/A
5
NA
BRL-101, Autologous hematopoietic stem and progenitor cells injection
Bioray Laboratories, Nanfang Hospital, Southern Medical University
Sickle Cell Disease
10/25
05/26
NCT06287086: Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease

Not yet recruiting
N/A
1
NA
BRL-101 autologous hematopoietic stem and progenitor cells injection, BRL-101
Bioray Laboratories, Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College
Sickle Cell Disease
08/25
06/26
NCT06300723: Clinical Study of BRL-101 in Severe SCD

Enrolling by invitation
N/A
3
RoW
BRL-101, Autologous hematopoietic stem and progenitor cells injection
Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University
Sickle Cell Disease
03/26
06/26
NCT06298630: Long-term Follow-up Study of BRL-101 for TDT

Not yet recruiting
N/A
45
RoW
Assessments
Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, Shenzhen Children 's Hospital
Thalassemia, Beta
08/38
10/38
BRL-303 / BRL Medicine
NCT06681337: Universal CAR-T Cell Therapy for Refractory Lupus Nephritis

Not yet recruiting
1
10
NA
BCMA CART + CD19 CART
Bioray Laboratories, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lupus Nephritis
12/25
12/25
NCT06485232: Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.

Not yet recruiting
1
25
RoW
Universal BCMA CAR-T, Universal CD19 CAR-T, Universal BCMA CAR-T; Universal CD19 CAR-T
Xuanwu Hospital, Beijing, Bioray Laboratories
Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized, Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
12/26
12/27
BRL-302 / BRL Medicine
NCT06633042: The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD

Not yet recruiting
1
18
NA
Universal BCMA-CD19 CART, BRL-302
Bioray Laboratories, Wenzhou Medical University Affiliated Ophthalmology Hospital
Autoimmune Disease
10/25
12/25
NCT06895811: Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC

Recruiting
1
3
RoW
PSMA-UCAR T (BRL-302)
Shanghai Changzheng Hospital, Bioray Laboratories
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
11/25
11/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bimzelx (bimekizumab-bkzx) / UCB
BeNeBio, NCT04340076: Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Active, not recruiting
4
244
Europe
Secukinumab, Cosentyx, Ixekizumab, Taltz, Brodalumab, Kyntheum, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tildrakizumab, Ilumetri, Bimekizumab, Bimzelx
Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Belgium Health Care Knowledge Centre, University Hospital, Ghent
Psoriasis, Psoriasis Vulgaris
12/25
12/25
NCT05499416: Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

Withdrawn
4
20
NA
Bimekizumab, BIMZELX®
Innovaderm Research Inc., Ciusss de L'Est de l'Île de Montréal
Psoriasis Vulgaris, Active Psoriatic Arthritis
09/23
04/24
NCT06336343: Bimekizumab in Plaque Psoriasis

Recruiting
4
60
US
Bimekizumab
Icahn School of Medicine at Mount Sinai, UCB Pharma, Psoriasis Treatment Center of Central New Jersey
Plaque Psoriasis
10/25
10/25
BE RADIANT, NCT03536884 / 2017-003784-35: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Checkmark Efficacy and safety data from BE RADIANT in moderate to severe plaque psoriasis
Apr 2021 - Apr 2021: Efficacy and safety data from BE RADIANT in moderate to severe plaque psoriasis
Checkmark From BE RADIANT trial for psoriasis at AAD 2021
Feb 2021 - Feb 2021: From BE RADIANT trial for psoriasis at AAD 2021
Checkmark From BE RADIANT trial for psoriasis
More
Completed
3
743
Europe, Canada, US, RoW
Bimekizumab, UCB4940, Secukinumab, COSENTYX®, Placebo, PBO
UCB Biopharma SRL
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
09/19
08/23
BE HEARD I, NCT04242446 / 2019-002550-23: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Hourglass Jan 2023 - Jun 2023 : Data from BE HEARD I trial for moderate-to-severe hidradenitis suppurativa
Completed
3
505
Europe, Canada, US, RoW
Bimekizumab, UCB4940, Placebo, PBO
UCB Biopharma SRL
Hidradenitis Suppurativa
04/22
02/23
BE MOBILE 1, NCT03928704 / 2017-003064-13: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

Checkmark Data from BE MOBILE 1 and BE MOBILE 2 trials for active axial spondyloarthritis (axSpA)
Jan 2023 - Jan 2023: Data from BE MOBILE 1 and BE MOBILE 2 trials for active axial spondyloarthritis (axSpA)
Checkmark From BE MOBILE 1 trial for axial spondyloarthritis
Jan 2022 - Jan 2022: From BE MOBILE 1 trial for axial spondyloarthritis
Completed
3
274
Europe, Japan, US, RoW
Bimekizumab, BKZ, UCB4940, Placebo, PBO
UCB Biopharma SRL
Nonradiographic Axial Spondyloarthritis
06/22
04/23
BE BRIGHT, NCT03598790 / 2016-003427-30: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Checkmark Efficacy and safety data from BE SURE and BE BRIGHT trials for moderate to severe plaque psoriasis
Sep 2021 - Sep 2021: Efficacy and safety data from BE SURE and BE BRIGHT trials for moderate to severe plaque psoriasis
Checkmark Efficacy and safety data from BE BRIGHT open-label extension trial for psoriasis
Aug 2021 - Aug 2021: Efficacy and safety data from BE BRIGHT open-label extension trial for psoriasis
Completed
3
1353
Europe, Canada, Japan, US, RoW
Bimekizumab, UCB4940
UCB Biopharma SRL
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
11/23
11/23
BE TOGETHER, NCT06425549: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Recruiting
3
168
Europe, Canada, Japan, US, RoW
bimekizumab, BKZ, UCB4940, ustekinumab, USTE, placebo
UCB Biopharma SRL
Moderate to Severe Plaque Psoriasis
08/28
11/30
BE UNIQUE, NCT06506916: A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Recruiting
3
90
Europe, US
bimekizumab, BKZ
UCB Biopharma SRL
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
04/26
03/28
NCT06624228: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

Recruiting
3
550
Europe, Canada, Japan, US, RoW
Bimekizumab, Risankizumab, Placebo
UCB Biopharma SRL
Psoriatic Arthritis
03/26
07/26
NCT06668181: An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Recruiting
3
40
Europe, Canada
Bimekizumab
UCB Biopharma SRL
Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
02/28
06/30
NCT06921850: A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

Recruiting
3
40
US
Bimekizumab
UCB Biopharma SRL
Hidradenitis Suppurativa
03/27
05/29
BE SHINING, NCT06011733: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

Completed
3
133
RoW
Placebo, Bimekizumab, BKZ
UCB Biopharma SRL
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
02/25
02/25
BE VITAL, NCT04009499 / 2018-004725-86: A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Active, not recruiting
3
1131
Europe, Canada, Japan, US, RoW
Bimekizumab, BKZ, UCB4940
UCB Biopharma SRL
Psoriatic Arthritis
05/26
05/26
BE HEARD EXT, NCT04901195 / 2020-004179-42: A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Active, not recruiting
3
658
Europe, Canada, Japan, US, RoW
Bimekizumab, UCB4940
UCB Biopharma SRL
Hidradenitis Suppurativa
07/26
07/26
BE MOVING, NCT04436640 / 2019-004163-47: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Active, not recruiting
3
508
Europe, Japan, US, RoW
Bimekizumab, BKZ, UCB4940
UCB Biopharma SRL
Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
08/26
08/26
BE CONNECTED, NCT04718896 / 2020-001724-34: A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

Completed
2
41
Europe, Canada, US
bimekizumab, BKZ, UCB4940
UCB Biopharma SRL
Moderate to Severe Plaque Psoriasis
03/25
03/25
EARLYPSO, NCT06742333: Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?

Recruiting
2
40
Europe
Bimekizumab, Clobetasol
Centre Hospitalier Universitaire de Nice
Psoriasis
04/28
10/28
NCT05292131: A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Completed
1
121
Europe, US
bimekizumab, BKZ; UCB4940
UCB Biopharma SRL
Healthy Study Participants
01/23
01/23
BE CARING, NCT06888193: A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Recruiting
1
20
Canada
Bimekizumab, Bimzelx®
UCB Biopharma SRL
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
05/27
05/27
NCT06786936: Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms

Recruiting
N/A
50
Europe
Secukinumab, N/A (Not applicable), Bimekizumab, Ixekizumab, Placebo
NHS Greater Glasgow and Clyde, University of Glasgow, Medical Research Council
Psoriatic Arthritis, Depression, Psoriatic Plaque
02/27
04/27
BRL-301 / BRL Medicine
NCT05381181: Safety and Efficacy Evaluation of Next-generation CD19-UCART

Not yet recruiting
1
20
NA
CD19-UCART
Bioray Laboratories, The First Affiliated Hospital of Zhengzhou University
Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
05/24
05/26
NCT05859997: Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases

Enrolling by invitation
N/A
15
RoW
BRL-301, Allogeneic Anti-CD19 CAR T cells
Bioray Laboratories, Shanghai Changzheng Hospital
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated Systemic Vasculitis, Antiphospholipid Syndrome
05/24
05/25
NCT05988216: Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

Recruiting
N/A
12
RoW
BRL-301, Allogeneic Anti-CD19 CAR T cells
Bioray Laboratories, First Affiliated Hospital of Zhejiang University
Systemic Lupus Erythematosus (SLE)
12/24
09/25
BRL-201 / BRL Medicine
2022-BRL-201, NCT05741359: The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Recruiting
1
18
RoW
CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection, BRL-201
Bioray Laboratories, Institute of Hematology ＆ Blood Diseases Hospital，Chinese Academy of Medical Sciences, Zhejiang University, Wuhan Union Hospital, China
Non-hodgkin Lymphoma,B Cell
01/24
03/24
2019-CAR-00CH1, NCT04213469: PD1-CD19-CART in Patients With r/r B-cell Lymphoma

Completed
N/A
20
RoW
PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells, PD1-CD19-CART
Bioray Laboratories, First Affiliated Hospital of Zhejiang University
B-cell Lymphoma
11/21
11/23
BRL-101 / BRL Medicine
NCT05577312: Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

Enrolling by invitation
1
9
RoW
BRL-101, BRL-101 autologous hematopoietic stem and progenitor cells injection
Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University
Beta-Thalassemia
08/25
09/26
NCT06287099: Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease

Not yet recruiting
N/A
5
NA
BRL-101, Autologous hematopoietic stem and progenitor cells injection
Bioray Laboratories, Nanfang Hospital, Southern Medical University
Sickle Cell Disease
10/25
05/26
NCT06287086: Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease

Not yet recruiting
N/A
1
NA
BRL-101 autologous hematopoietic stem and progenitor cells injection, BRL-101
Bioray Laboratories, Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College
Sickle Cell Disease
08/25
06/26
NCT06300723: Clinical Study of BRL-101 in Severe SCD

Enrolling by invitation
N/A
3
RoW
BRL-101, Autologous hematopoietic stem and progenitor cells injection
Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University
Sickle Cell Disease
03/26
06/26
NCT06298630: Long-term Follow-up Study of BRL-101 for TDT

Not yet recruiting
N/A
45
RoW
Assessments
Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, Shenzhen Children 's Hospital
Thalassemia, Beta
08/38
10/38
BRL-303 / BRL Medicine
NCT06681337: Universal CAR-T Cell Therapy for Refractory Lupus Nephritis

Not yet recruiting
1
10
NA
BCMA CART + CD19 CART
Bioray Laboratories, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lupus Nephritis
12/25
12/25
NCT06485232: Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.

Not yet recruiting
1
25
RoW
Universal BCMA CAR-T, Universal CD19 CAR-T, Universal BCMA CAR-T; Universal CD19 CAR-T
Xuanwu Hospital, Beijing, Bioray Laboratories
Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized, Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
12/26
12/27
BRL-302 / BRL Medicine
NCT06633042: The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD

Not yet recruiting
1
18
NA
Universal BCMA-CD19 CART, BRL-302
Bioray Laboratories, Wenzhou Medical University Affiliated Ophthalmology Hospital
Autoimmune Disease
10/25
12/25
NCT06895811: Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC

Recruiting
1
3
RoW
PSMA-UCAR T (BRL-302)
Shanghai Changzheng Hospital, Bioray Laboratories
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
11/25
11/25

Download Options